Misleading Drug Ads Should Be Subject To Financial Penalties, AARP Says
This article was originally published in The Pink Sheet Daily
Congress should implement financial penalties for misleading drug ads, AARP Executive Director for State & National Initiatives Christopher Hansen said
You may also be interested in...
Merck, GSK, Lilly and PhRMA will not voluntarily limit price increases as AARP requested. The tone of the responses, the seniors' group noted, has been cooperative. Several manufacturers suggested a meeting with AARP as the next step.
Legislation would allow FDA to pre-approve ads from repeat offenders. TV ads would need to include full MedGuide information. Draft language also calls for ad disclaimers on new drugs for two years.
FDA’s draft guidance on systemic lupus erythematosus drug development lists four possible claims that the agency “may be willing to approve”: reduction in disease activity; organ-specific lupus treatment; complete clinical response/remission; and reduction in flares.